Endogenous b-galactose-binding lectins have many biological functions, but their biological significance in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) remains unclear. By immunohistochemistry, we analyzed the expression of galectin-1 and galectin-3 in HL and ALCL cases as well as in cell lines, and investigated the pharmacological effects of galectin-1 treatment with and without CD30 pre-stimulation of HL and ALCL cell lines. The galectin-3-negative human embryonic kidney cell line (HEK-293) was transfected with galectin-3 cDNA. Galectin-3 is differentially expressed in HL and ALCL. CD30 stimulation of the ALCL cell line Karpas 299 activates NF-kB without induction of apoptosis. Galectin-1 treatment of Karpas 299 induces cell death, which is significantly increased by CD30 pre-stimulation. The CD30-mediated increase of galectin-1-induced cell death is to some extent caspase independent and does not influence the expression of tumor necrosis factor-associated factor 1 (TRAF1), TRAF2, and cellular inhibitor of apoptosis 2 protein (cIAP2), as revealed in Karpas 299 cells. In other cell lines except Karpas 299, CD30 pre-stimulation did not significantly enhance galectin-1-induced cell death. Galectin-3 transfection of HEK-293 cells resulted in cell surface expression of galectin-3, associated with marked cell aggregation. CD30-targeted therapy in combination with galectin-1 treatment may induce effective killing of ALCL cells but not of HL cells.
Galectin is a member of the family of endogenous mammalian b-galactoside-binding lectins that appears to be involved in a variety of biological phenomena.
1,2 Galectin regulates cell growth 3 and apoptosis. 4 Galectin-1 is a useful marker for differentiation between classical Hodgkin lymphoma (cHL) and nodular lymphocyte predominant Hodgkin lymphoma 5 or between cHL and diffuse large B-cell lymphoma (DLBCL). 6 In addition, alterations of N-glycans on the cell surface can regulate cell death in DLBCL by interacting with galectin- 1. 7 CD30 is a member of the TNF receptor family, which is almost selectively expressed on the Hodgkin-Reed-Sternberg (HRS) cells of cHL as well as the tumor cells of anaplastic large cell lymphoma (ALCL), DLBCL of the anaplastic variant, and embryonal carcinoma of the testis. CD30 lacks an intracellular death domain. Stimulation of CD30 leads to NF-kB activation and the induction of anti-apoptotic mechanisms. 8 Galectin-3 is expressed in ALCL and is a useful marker for differentiation between ALCL and cHL, 9 as well as for differentiation between DLBCL and Burkitt's lymphoma. 10 Galectin-3 represents a novel anti-apoptotic molecule containing the bcl-2 family BH1 domain that inhibits cytochrome c release from mitochondria. 11 In contrast, secreted extracellular galectin-3 can induce apoptosis through the interaction with terminal galactose residues of cell surface glycans. 12 We reported that alterations of N-glycans and cell surface sialic acid can regulate galectin-3-induced apoptosis in DLBCL, which is consistent with the finding that N-glycans and cell surface sialic acid represent one of the molecules that are associated with tolerance to galectin-3-induced apoptosis of DLBCL. 13 Hahn et al. 14 reported that galectin-3 can inhibit galectin-1-induced apoptosis in Jurkat cell line. Noteworthy, in cHL and ALCL, the biological function of galectin-1 and galectin-3 remains unclear. We analyze the expression pattern of galectin-1 and galectin-3 in cHL and ALCL by immunohistochemistry, and investigated the pharmacological effects of galectin-1 treatment in combination with and without CD30 stimulation of cHL and ALCL cell lines.
MATERIALS AND METHODS Tissue Microarray
To prepare tissue microarrays (TMAs), tissue cores (1 mm in diameter) were removed from representative areas of the FFPE blocks of all samples and inserted into a recipient paraffin block. Sections were cut from the newly assembled TMA and used for immunohistochemical analysis. The TMA was prepared from 6 cases of cHL and 19 cases of ALCL. In addition, 10 ALCL cell lines (Mac-1, Mac-2a, Mac-2b, JK, FE-PD, Sup-M2, Karpas 299, JB6, SU-DHL1, and SR786) and 4 HL cell lines (L1236, HDLM2, KMH2, and L540) were included.
Immunohistochemical Stainings
Immunocytochemistry was carried out as published. 9 In brief, immunohistologic stainings using galectin-1, AF1152, and galectin-3 from R&D Systems (Wiesbaden, Germany) as primary antibodies were performed on TMA sections. Before incubation with the primary antibody, the dewaxed sections were subjected to an antigen retrieval protocol consisting of a brief, high-temperature heating of the sections immersed in a citrate buffer (10 mM, pH 6.0) for 2 min in a high-pressure cooker. Bound antibodies were made visible using the streptavidin biotin-alkaline phosphatase method and FastRed as chromogen. All incubations were performed in an automated immunostainer (TechMate 500 Dako). All reagents for that purpose were purchased from DAKO. Results were evaluated as follows: cases with 430% positive tumor cells were graded positive and cases with o30% of positive tumor cells were graded negative.
Cell Lines and Treatments
We used the B cell-derived HL cell lines, L1236, L428, KMH2 and the T cell-derived HL cell line HDLM2. The ALCL cell line, Karpas 299 was obtained from German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). The ALCL cell lines JB6 and FE-PD were generous gifts from Dr ME Kadin (Harvard Medical School, Boston, MA) and Dr K Pulford (John Radcliff Hospital, University of Oxford, Oxford, UK), respectively. The cell lines Karpas 299, JB6 are t(2;5) positive. Cells were maintained in RPMI-1640 with glutamine (4 mM; Gibco-BRL, Eggenstein, Germany) and 10% (v/v) heat-inactivated fetal calf serum at 5% CO 2 Cells were galectin-1 treated (5 mM bovine splenic galaptin, Sigma) or control treated (0.05 M Tris) for 24 h. For co-stimulation experiments, cells were CD30 pre-stimulated and galectin-1 treated. Induction of cell death was analyzed by FACS. The 5 mM concentration of galectin-1 was applied, because the concentration of galectin-1 to induce cell death is ranging from 4 to 16 mM as previously described. 4 We performed western blot analysis of tumor necrosis factor-associated factor 1 (TRAF1), TRAF2, and cellular inhibitor of apoptosis 2 protein (cIAP2) of CD30/controltreated Karpas 299 cells as well as Karpas 299 cells that have been CD30 pre-stimulated for 24 h, followed by 5 mM galectin-1 treatment for 6 h, by immunoblot.
The pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD-fmk) (Calbiochem, Schwalbach, Germany) was used at 50 mM with a preincubation of 3 h.
Immunoblot Analysis
Cell extracts (24 mg) were fractioned on 4-12% (w/v) SDSpolyacrylamide gels and transferred onto PVDF membranes (Amersham, Braunschweig, Germany). Immunoblot analysis was performed by TRAF2 (BD Pharmingen, dilution 6:1000), cIAP2 (Abcam, Cambridge, UK, ab32059, dilution 1:1000), TRAF 1 (produced in the Institute of Pathology, Charité Berlin, dilution 1:50), b-actin (Abcam), and galectin-3 (MAB1154, R&D Systems). Primary antibodies were detected by HRP-conjugated antibodies and chemiluminescence (Amersham).
Flow-Cytometric Analysis
Staining of dead/apoptotic cells was performed by Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences Pharmingen, Wiesbaden-Nordenstadt, Germany) according to the manufacturer's instructions. Galectin-3 is detected by galectin-3 antibody (R&D Systems) and second anti-mouse FITC-conjugated antibody (DakoCytomation). Labeled cells were analyzed by FACSort (Becton Dickinson, Heidelberg, Germany). Protein and RNA analysis was performed as described. 8 RNA Extraction and RT-RQ-Real Time PCR RT-RQ-PCR was carried out as published. 8 The following pairs of oligonucleotides (forward/reverse) were used: Figure 1a ) and ALCL tumor cells by immunohistology (Figure 1b) . On the other hand, all cases of HL are galectin-3 negative (Figure 1c ) and almost all ALCL cases were galectin-3 positive (Figure 1d ). There is no difference in galectin-3 expression between ALK-positive and ALK-negative ALCL cases (Table 1) . Galectin-3 expression is significantly different in cHL and ALCL (w 2 -test, *P ¼ 0.0000042, Table 1 ).
Knockdown of Galectin-3 by siRNA
galectin-3 5 0 -CAATTCTGGGCACGGTGAA-3 0 /5 0 -CATCATT CCCTCTTTGGAAATCTAA-3 0 , Hypoxanthine phosphori- bosyltransferase (HPRT) 5 0 -GAGTCCTATTGACATCGCCAG TA-3 0 /5 0 -CTAAGCAGATGGCCACAGAACTAG-3
Galectin-1-Induced Cell Death
Galectin-1 treatment (5 mM) for 24 h induces cell death in the HL cell lines KMH2 (47%) as well as in the ALCL cell lines Karpas 299 (40%) and SR786 (79%) (Figure 2a ), but in L428 only 3% of all cells suggesting that L428 is tolerant to galectin-1-induced cell death. There is heterogeneity of galectin-1-induced cell death among cell lines (Figure 2b) . At 48 h of galectin-1 treatment, almost all cell lines underwent massive cell death (data not shown).
Influence of CD30 Pre-Stimulation on Galectin-1-Induced Cell Death Galectin-1-induced cell death is enhanced by CD30 pre-stimulation of Karpas 299 (Figure 3a) . Galectin-1-induced cell slightly increase by CD30 pre-stimulation of DEL, but it is not statistically significant (Figure 3b) and JB6 (Figure 3c ). Galectin-1 could not induce cell death in combination with CD30 pre-stimulation of L428 (Figure 3d ) and galectin-1 could not be influenced by CD30 pre-stimulation of L1236 cells (Figure 3e ). CD30 pre-stimulation slightly decreases galectin-1-induced cell death in KMH2 (Figure 3f ) and HDLM2 cells (Figure 3g ), but there is no significant.
Caspase Inhibition Completely Inhibited Galectin-1-Induced Cell Death Whereas a Significant Proportion of CD30/Galectin-1-Induced Cell Death Remained Unaffected Galectin-1-induced cell death was significantly inhibited by the pan-caspase inhibitor z-VAD-fmk in Karpas 299 cells. CD30-mediated enhancement of galectin-1-induced cell death was significantly inhibited by z-VAD-fmk, ie, cell death decreased from 78 to 20%, where about 10-15% of cell death remained unaffected by caspase inhibition (Figure 3h ).
TRAF1, TRAF2, and cIAP2 Expression of CD30-Stimulated and Galectin-1-Treated Karpas 299 Cells
Consistent with published data, CD30 stimulation increased the expression of TRAF1 and cIAP2 but decreased the expression of TRAF2 at 24 h. Galectin-1 treatment for 6 h did Table 1 Galectin-1 and galactin-3 expression in ALCL and HL
Cell lines
Gal-1(+) Gal-1(À) Cases Gal-1(+) Gal-1(À) Galectin
DISCUSSION
We previously reported that galectin-1 can induce cell death in DLBCL, 7 suggesting that endogenous lectin might be a regulator of cell death in this lymphoma entity. Here, we demonstrate that galectin-1 can induce cell death in HL and ALCL cell lines as well. Therefore, galectin-1 might exhibit a universal role in the induction of cell death, regardless of histological subtypes of human malignant lymphoma.
Stein et al. 16 described the CD30 antigen to be expressed in reactive and neoplastic lymphoid tissues. Dürkop et al. 17 revealed that CD30 belongs to the TNFR superfamily. Hübinger et al. 18 reported that the cellular inhibitors of apoptosis proteins, eg, cIAP1 and cIAP2 are induced by CD30 stimulation in ALCL cells. Hirsch et al. 8 reported that CD30-induced signaling is absent in HL cells but present in ALCL cells. Hübinger et al. 19 and Hirsch et al. 8 revealed that CD30 stimulation did not induce apoptosis in ALCL cell lines. In the present study, we demonstrated that galectin-1-induced cell death is significantly increased by CD30 prestimulation of ALCL cells. These data suggest an interference of galectin-1 and CD30 signaling, where a caspase-dependent (galectin-1 mediated) and to some extent a caspase-independent pathway (CD30 signaling, Figure 3h ) is activated to induce cell death. The CD30 pre-stimulation is not effective in all HL and some ALCL cell lines. In L428, L1236, KMH2, HDLM2, DEL, and JB6 cells, galectin-1-induced cell death was not significantly altered by CD30 pre-stimulation. Published data demonstrate heterogeneous effects of CD30 stimulation in different lymphoma cell lines. 20 Hirsch et al. . This CD30 effect is not present in HL cell lines, which is concordant with published data, where Hodgkin cell lines are shown to be explained by the fact that there is no CD30 signaling in Hodgkin cell lines. 8 In ALCL cell lines, DEL and JB6, CD30 stimulation could not significantly enhance galectin-1-induced cell death. While CD30 can enhance galectin-1-induced cell death in Karpas 299, the reason why CD30 could not enhance galectin-1-induced cell death in DEL and JB6 is under future investigation.
In order to clarify the interaction between galectin-1-induced cell death and CD30 signaling, we focused on the cell line Karpas 299. CD30 belongs to the subclass of the TNFR family without a death domain. Instead, adaptor molecules like TRAF1, TRAF2, TRAF3, and TRAF5 interact with the cytoplasmic domain of CD30 to transmit the signal. [21] [22] [23] TRAF1 is an anti-apoptotic molecule of the intracellular signaling pathway of TNFR family, the expression of which is induced by CD30 stimulation. 24 We confirmed that CD30 stimulation induced TRAF1 expression in Karpas 299, and in the present study we revealed that galectin-1 treatment did not influence this regulation (Figure 4) . The CD30-mediated downregulation of TRAF2 is known to be a mechanism which negatively regulates CD30-induced NF-kB activation. 25 Our experiments revealed that CD30-mediated TRAF2 downregulation is not affected by galectin-1 treatment in Karpas 299 cells. cIAP2 is highly expressed in HRS cells and inhibits apoptosis by interfering with constitutively active caspase-3. CD30 stimulation induces cIAP2 expression through NF-kB activation in ALCL cells. 26 Our study demonstrates that galectin-1 treatment did not influence CD30-mediated cIAP2 induction. Therefore, a TRAF1, TRAF2, and cIAP2-independent pathway is activated by CD30 stimulation triggering the enhancement of galectin-1-induced cell death, which is to some extent caspase independent. CD45RO is known to be a receptor for galectin-1. 27 According to our preliminary analysis, CD45RO expression of HL and ALCL cell lines is closely correlated with the sensitivity to galectin-1 (data not shown). Therefore, we assume that CD45RO is a receptor for galectin-1 in HL and ALCL cell lines. Galectin-1 and 3 are associated with the biology of human lymphoma cells O Suzuki et al
